⌘K
Loading ticker…
As of 2026-08-24, Rhythm Pharmaceuticals, Inc. Common Stock (RYTM) has a 3-month relative strength percentile of 86 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 54. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 4.7%, relative volume 0.55×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
RYTM is held by 27 ETFs as of May 2026. Top owner: SCHA at 0.11% weight, $26M notional. Top 3 carry $65M.
Held by 68 ETFs · $869M across latest filings · largest weight 3.79% (MEDI).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| SCHASchwab U.S. Small-Cap ETF | 0.11% | $26M | −0.02 pp |
| VTWO | 0.14% | $24M | −0.02 pp |
| VHTVanguard Health Care ETF | 0.08% | $15M | — |
| VTWG | 0.26% | $4M | −0.05 pp |
| SCHBSchwab U.S. Broad Market ETF | 0.01% |
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| $3M |
| — |
| MSSM | 0.36% | $3M | −0.01 pp |
| ONEQ | 0.01% | $1M | — |
| VFMO | 0.08% | $1M | −0.14 pp |
| ESML | 0.06% | $1M | — |
| GSC | 0.51% | $1M | −0.18 pp |
Showing 10 of 27 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | RYTM Jan avg: -2.05% median: -4.13% win: 25% σ: 5.55% n: 4 2022-04-12 → 2026-07-31 | RYTM Feb avg: -7.46% median: -8.58% win: 0% σ: 4.18% n: 4 2022-04-12 → 2026-07-31 | RYTM Mar avg: -9.14% median: -4.87% win: 0% σ: 11.91% n: 4 2022-04-12 → 2026-07-31 | RYTM Apr avg: -1.77% median: -6.45% win: 40% σ: 20.70% n: 5 2022-04-12 → 2026-07-31 | RYTM May avg: -14.02% median: -10.26% win: 20% σ: 19.77% n: 5 2022-04-12 → 2026-07-31 | RYTM Jun avg: 12.69% median: 15.08% win: 80% σ: 11.40% n: 5 2022-04-12 → 2026-07-31 | RYTM Jul avg: 50.70% median: 17.41% win: 80% σ: 87.04% n: 5 2022-04-12 → 2026-07-31 | RYTM Aug avg: 36.07% median: 33.41% win: 75% σ: 34.82% n: 4 2022-04-12 → 2026-07-31 (current) | RYTM Sep avg: 1.31% median: 3.16% win: 50% σ: 10.41% n: 4 2022-04-12 → 2026-07-31 | RYTM Oct avg: 1.82% median: 1.77% win: 75% σ: 8.83% n: 4 2022-04-12 → 2026-07-31 | RYTM Nov avg: 19.22% median: 18.17% win: 75% σ: 22.15% n: 4 2022-04-12 → 2026-07-31 | RYTM Dec avg: 8.66% median: 3.45% win: 50% σ: 20.68% n: 4 2022-04-12 → 2026-07-31 |